BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19096962)

  • 21. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
    Gelmini S; Tricarico C; Petrone L; Forti G; Amorosi A; Dedola GL; Serio M; Pazzagli M; Orlando C
    Clin Chem Lab Med; 2003 Mar; 41(3):261-5. PubMed ID: 12705330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen.
    Jaakkola S; Vornanen T; Leinonen J; Rannikko S; Stenman UH
    Clin Chem; 1995 Feb; 41(2):182-6. PubMed ID: 7533062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of a diagnostic test system for early non-invasive detection of prostate cancer based on PCA3 mRNA levels in urine sediment using quantitative reverse tanscription polymerase chain reaction (qRT-PCR)].
    Pavlov KA; Shkoporov AN; Khokhlova EV; Korchagina AA; Sidorenkov AV; Grigor'ev MÉ; Pushkar' DIu; Chekhonin VP
    Vestn Ross Akad Med Nauk; 2013; (5):45-51. PubMed ID: 24000667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-inducible factor-1 in human breast and prostate cancer.
    Kimbro KS; Simons JW
    Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer.
    Straub B; Müller M; Krause H; Schrader M; Miller K
    Urology; 2003 Jul; 62(1):172-6. PubMed ID: 12837461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.
    Gillatt D; Reynard JM
    Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
    Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
    Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
    Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
    Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
    Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
    J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
    Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
    Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha.
    Wei H; Wang C; Chen L
    Pancreas; 2006 Mar; 32(2):159-63. PubMed ID: 16552335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative real-time rt-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients.
    Straub B; Müller M; Krause H; Schrader M; Miller K
    Oncology; 2003; 65 Suppl 1():12-7. PubMed ID: 12949428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.
    Li H; Bubley GJ; Balk SP; Gaziano JM; Pollak M; Stampfer MJ; Ma J
    Prostate; 2007 Sep; 67(12):1354-61. PubMed ID: 17624927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.